← Back to Search

Immunomodulator

Evorpacept for Cancer

Phase 1

Waitlist Available

Research Sponsored by ALX Oncology Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 28 days

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new drug, evorpacept, to see if it is effective in treating advanced solid tumors and lymphoma.

Who is the study for?

This trial is for people with advanced solid tumors or relapsed/refractory Non-Hodgkin's lymphoma without standard treatment options. Participants must be in good physical condition, have proper bone marrow, kidney and liver function, and not have received certain prior treatments like high-dose chemotherapy with stem cell rescue.

What is being tested?

The study is testing Evorpacept (ALX148) combined with other cancer drugs like Pembrolizumab and Trastuzumab to find the safest dose that works. It's a phase 1 trial which means it's early in the testing process and focuses on safety.

What are the potential side effects?

Potential side effects may include reactions at the injection site, fatigue, nausea, lowered blood counts leading to increased infection risk or bleeding problems. Since this is an early-phase trial, there might be unknown side effects as well.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 28 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 28 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 28 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Dose-limiting toxicities (Number of participants with a DLT)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

6Treatment groups

Experimental Treatment

Group I: Evorpacept (ALX148) + Trastuzumab + Ramucirumab + PaclitaxelExperimental Treatment3 Interventions

The Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab + ramucirumab + paclitaxel infusions.

Group II: Evorpacept (ALX148) + TrastuzumabExperimental Treatment2 Interventions

The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab infusions.

Group III: Evorpacept (ALX148) + RituximabExperimental Treatment2 Interventions

The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with rituximab infusions.

Group IV: Evorpacept (ALX148) + Pembrolizumab + 5FU + PlatinumExperimental Treatment3 Interventions

The Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab + 5FU + platinum infusions.

Group V: Evorpacept (ALX148) + PembrolizumabExperimental Treatment2 Interventions

The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab infusions.

Group VI: Evorpacept (ALX148)Experimental Treatment1 Intervention

The Part 1 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Rituximab

1999

Completed Phase 4

~2990

Pembrolizumab

2017